For a pdf copy of my complete CV, click here.
Harvard Medical School
Faculty, Center for Bioethics (2015- )
Brigham and Women’s Hospital
Research Scientist, Department of Medicine (2017- )
Research Fellow, Department of Medicine (2015-2017)
Visiting Researcher, Center for Philosophy and History of Science (2015- )
Research Fellow, Biomedical Ethics Unit (2012-2015)
Instructor, Department of Philosophy (2015)
Ph.D. Philosophy, University of Western Ontario (2012)
M.A. Philosophy, University of Western Ontario (2006)
B.A. (Honors) Philosophy, University of Illinois at Chicago (2004)
Canadian Institutes of Health Research, Project Grant (2017-2021)
Co-investigator, “Developing a Framework for the Ethical Design and Conduct of Pragmatic Trials”
Laura and John Arnold Foundation (2017-2020)
Principal Investigator, “Program on Regulation, Therapeutics, and Law (PORTAL) Biomarker Research Consortium”
Canadian Institutes of Health Research, Project Grant (2016-2020)
Co-investigator, “Ethics, Efficiency, and Patient Burden in Drug Development”
Hey SP, Weijer C, Taljaard M, Kesselheim AS (2018). Research Ethics for Emerging Trial Designs: Does Equipoise Need to Adapt? BMJ 360:k226.
Hey SP, London AJ, Weijer C, Rid A, Miller F (2017). Is The Concept of Clinical Equipoise Still Relevant to Research? BMJ 359:j5787.
Hey SP (2017). Ethical Challenges in Biomarker-Driven Drug Development. Clinical Pharmacology & Therapeutics 103:23-25.
Hey SP, Cohen IG, Adashi EY, Kesselheim AS (2017). Influence, Integrity, and the FDA: An Ethical Framework. Science 357(6354):876-877.
Hey SP, Franklin JM, Avorn J, Kesselheim AS (2017). Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors. Circulation: Cardiovascular Quality and Outcomes 10(6):e003121.
Hey SP (2017). Clinical trial participants should have a say in new drug pricing. STAT News, May 18.
Hey SP & Barsanti-Innes B (2017). Epistemology, Ethics, and Progress in Precision Medicine. Perspectives in Biology and Medicine 59(3):293-310.
Hey SP & Kesselheim AS (2017). Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social Considerations. Hastings Center Report 47(2):16-20.
Hey SP (2017). Priority, Prediction and the Ethical Research Enterprise. Journal of Medical Ethics 43(12):812-813.
Barsanti-Innes B, Hey SP, & Kimmelman J (2017). The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing. The Oncologist 22(1):89-96.
“Visualizing Clinical Research Portfolios.” Research Ethics Consortium, Harvard Medical School; November 2017.
“Assay Validation and Ethical Challenges in Precision Medicine: A Case Study of BRAF Mutation Testing in Metastatic Melanoma.” Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital; September 2017.
“Precision Medicine and Pragmatic Trials: Friends or Foes?” Annual Society for Clinical Trials Meeting, Liverpool, UK; May 2017.
“Ethical Considerations in Pragmatic Cluster Randomized Trials.” Research Ethics Consortium, Harvard Medical School; February 2017.
“The Hope and Hype of Precision Medicine.” Health Policy and Bioethics Consortium, Harvard Medical School; November 2016.
“Explanation in Biomedicine: Diagnosing the Problems, Prescribing a Solution.” Reductionism and Integration, Bioethics and Behavior: A Conference Celebrating the Career of Kenneth F. Schaffner, University of Pittsburgh; September 2016.
“Explanatory Agnosticism in Translational Medicine” with James Overton. Society for Philosophy of Science in Practice (SPSP) Conference. Glassboro, NJ; June 2016.
“The Imprecision of Precision Medicine.” Department of Population Health, New York University Medical Center; February 2016.